GlassScriptPhysician profile
Katherine Arensmeyer
NPI 1609106517
$5,738.25
in general payments reported to CMS, 2019-2025
43 companies · $1,719 in 2025
The $1,719 reported for 2025 was more than what 92% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $215 · 2022: $589 · 2023: $1,289 · 2024: $1,925 · 2025: $1,719.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,567 · Education: $366.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,567.24 |
| Education | $366.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,052.46 | 2022-2025 | Darzalex, Tecvayli, Carvykti |
| Astrazeneca Pharmaceuticals LP | $581.19 | 2023-2025 | Imfinzi, Enhertu, Calquence |
| Karyopharm Therapeutics INC. | $406.15 | 2021-2024 | Xpovio |
| Pfizer INC. | $305.52 | 2024-2025 | |
| Glaxosmithkline, LLC. | $294.27 | 2023-2025 | Jemperli, Ojjaara, Zejula |
| Beigene USA, INC. | $271.43 | 2023-2025 | Brukinsa, Tevimbra |
| Abbvie INC. | $266.39 | 2024-2025 | |
| Lilly USA, LLC | $180.23 | 2023-2024 | Verzenio, Jaypirca, Retevmo |
| Daiichi Sankyo INC. | $177.42 | 2024-2025 | Enhertu |
| Astellas Pharma US INC | $166.55 | 2021-2025 | Padcev, Vyloy |
| Seagen INC. | $142.64 | 2022-2023 | Padcev |
| Secura Bio, INC. | $142.58 | 2021-2023 | Copiktra |
| Exelixis INC. | $133.91 | 2022-2025 | Cabometyx |
| Adc Therapeutics America, INC. | $131.86 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $109.68 | 2024-2025 | Fruzaqla, Ninlaro, Alunbrig |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Arensmeyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.